Fri, March 4, 2016
Thu, March 3, 2016
Wed, March 2, 2016
Tue, March 1, 2016
Mon, February 29, 2016
Fri, February 26, 2016
Thu, February 25, 2016
Wed, February 24, 2016
Tue, February 23, 2016
Mon, February 22, 2016
Fri, February 19, 2016
Thu, February 18, 2016
Wed, February 17, 2016
Tue, February 16, 2016
Fri, February 12, 2016
Thu, February 11, 2016
Wed, February 10, 2016
Tue, February 9, 2016
Mon, February 8, 2016
Fri, February 5, 2016
Thu, February 4, 2016
Wed, February 3, 2016
Tue, February 2, 2016
Mon, February 1, 2016

Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $120 on, Feb 16th, 2016

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-120-on-feb-16th-2016.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $152 to $120 on, Feb 16th, 2016.

Paul has made no other calls on ALNY in the last 4 months.



There is 1 other peer that has a rating on ALNY. Out of the 1 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.



This is the rating of the analyst that currently disagrees with Paul


  • Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016